JP2015520161A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520161A5 JP2015520161A5 JP2015512644A JP2015512644A JP2015520161A5 JP 2015520161 A5 JP2015520161 A5 JP 2015520161A5 JP 2015512644 A JP2015512644 A JP 2015512644A JP 2015512644 A JP2015512644 A JP 2015512644A JP 2015520161 A5 JP2015520161 A5 JP 2015520161A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- mammal
- nucleic acid
- aav
- vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648801P | 2012-05-18 | 2012-05-18 | |
| US61/648,801 | 2012-05-18 | ||
| PCT/US2013/031725 WO2013172964A1 (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207331A Division JP2019031564A (ja) | 2012-05-18 | 2018-11-02 | アミロイドの沈着を処置するための方法および組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520161A JP2015520161A (ja) | 2015-07-16 |
| JP2015520161A5 true JP2015520161A5 (enExample) | 2016-05-12 |
| JP6469000B2 JP6469000B2 (ja) | 2019-02-13 |
Family
ID=49584137
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512644A Active JP6469000B2 (ja) | 2012-05-18 | 2013-03-14 | アミロイドの沈着を処置するための方法および組成物 |
| JP2018207331A Pending JP2019031564A (ja) | 2012-05-18 | 2018-11-02 | アミロイドの沈着を処置するための方法および組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018207331A Pending JP2019031564A (ja) | 2012-05-18 | 2018-11-02 | アミロイドの沈着を処置するための方法および組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150183850A1 (enExample) |
| EP (1) | EP2850195B1 (enExample) |
| JP (2) | JP6469000B2 (enExample) |
| CN (2) | CN112574964A (enExample) |
| AU (1) | AU2013263346B2 (enExample) |
| BR (1) | BR112014028666B1 (enExample) |
| CA (1) | CA2873890C (enExample) |
| ES (1) | ES2786078T3 (enExample) |
| HK (1) | HK1207109A1 (enExample) |
| IN (1) | IN2014KN02672A (enExample) |
| RU (1) | RU2673484C2 (enExample) |
| WO (1) | WO2013172964A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975583A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2016196507A1 (en) | 2015-05-29 | 2016-12-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| US20180161395A1 (en) * | 2015-06-12 | 2018-06-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| JP7161401B2 (ja) * | 2016-04-14 | 2022-10-26 | 公益財団法人神戸医療産業都市推進機構 | アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物 |
| IL262784B2 (en) | 2016-05-18 | 2023-10-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
| NZ750291A (en) * | 2016-08-03 | 2021-07-30 | Univ South Florida | Reelin compositions for treatment of neurological disorders |
| CN110121356A (zh) * | 2016-09-02 | 2019-08-13 | 星火治疗股份有限公司 | 治疗cns疾病的方法和载体 |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| JP7361037B2 (ja) | 2017-10-03 | 2023-10-13 | プリベイル セラピューティクス，インコーポレーテッド | ライソゾーム病の遺伝子治療 |
| AU2018346102B2 (en) | 2017-10-03 | 2023-05-11 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| MX2022004524A (es) * | 2019-10-16 | 2022-07-21 | Univ Cornell | Tratamiento génico para la enfermedad de alzheimer. |
| KR20230020946A (ko) * | 2020-03-31 | 2023-02-13 | 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. | 중수소화 옥소페닐아르신 화합물 및 이의 용도 |
| CN116670291A (zh) * | 2020-11-25 | 2023-08-29 | 普利维尔治疗公司 | 用于神经退行性疾病的基因疗法 |
| US20250297279A1 (en) * | 2021-12-15 | 2025-09-25 | Genans Biotechnology Co., Ltd | Recombinant aav vectors and use thereof |
| CN116063405B (zh) * | 2022-09-27 | 2025-08-29 | 广州译码基因科技有限公司 | 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US6436996B1 (en) * | 1997-09-30 | 2002-08-20 | Duke University | Modulation of nitric oxide production |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| NZ555830A (en) * | 2004-12-15 | 2009-01-31 | Univ North Carolina | Chimeric vectors |
| DK1879623T3 (da) * | 2005-05-02 | 2012-12-17 | Genzyme Corp | Genterapi til rygmarvssygdomme |
| WO2008033375A2 (en) * | 2006-09-14 | 2008-03-20 | Medgenics Ltd. | Long lasting drug formulations |
| HUE027278T2 (en) * | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| CA2833912C (en) * | 2010-04-23 | 2021-09-21 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
-
2013
- 2013-03-14 IN IN2672KON2014 patent/IN2014KN02672A/en unknown
- 2013-03-14 JP JP2015512644A patent/JP6469000B2/ja active Active
- 2013-03-14 CN CN202011133829.0A patent/CN112574964A/zh active Pending
- 2013-03-14 CN CN201380038140.1A patent/CN104540952A/zh active Pending
- 2013-03-14 US US14/402,064 patent/US20150183850A1/en not_active Abandoned
- 2013-03-14 HK HK15107526.1A patent/HK1207109A1/xx unknown
- 2013-03-14 RU RU2014151218A patent/RU2673484C2/ru active
- 2013-03-14 AU AU2013263346A patent/AU2013263346B2/en active Active
- 2013-03-14 EP EP13790429.8A patent/EP2850195B1/en active Active
- 2013-03-14 BR BR112014028666-3A patent/BR112014028666B1/pt active IP Right Grant
- 2013-03-14 ES ES13790429T patent/ES2786078T3/es active Active
- 2013-03-14 WO PCT/US2013/031725 patent/WO2013172964A1/en not_active Ceased
- 2013-03-14 CA CA2873890A patent/CA2873890C/en active Active
-
2018
- 2018-11-02 JP JP2018207331A patent/JP2019031564A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520161A5 (enExample) | ||
| RU2014151218A (ru) | Способы и композиции для лечения амилоидных отложений | |
| Hajrasouliha et al. | Exosomes from retinal astrocytes contain antiangiogenic components that inhibit laser-induced choroidal neovascularization | |
| Asgari Taei et al. | The conditioned medium of human embryonic stem cell‐derived mesenchymal stem cells alleviates neurological deficits and improves synaptic recovery in experimental stroke | |
| Yousefi Dehbidi et al. | Mesenchymal stem cells and their derived exosomes to combat Covid–19 | |
| JP2018520646A5 (enExample) | ||
| JP2016500648A5 (enExample) | ||
| MX2016002152A (es) | Metodo para aumentar la expresion de proteinas codificadas por arn. | |
| JP2015518818A5 (enExample) | ||
| EA201500802A1 (ru) | Способы профилактики и/или лечения кардиомиопатии и устранения симптомов кардиомиопатии, фармацевтическая композиция, векторы | |
| CA2943185C (en) | Gene therapy for retinitis pigmentosa | |
| EP4378487A3 (en) | Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues | |
| EA201500923A1 (ru) | Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с | |
| EA201590353A1 (ru) | Способы лечения болезни альцгеймера и фармацевтические композиции | |
| WO2015158749A3 (de) | Viraler vektor für den zielgerichteten gentransfer in gehirn und rückenmark | |
| BR112015018252A2 (pt) | composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit | |
| PH12014500865A1 (en) | Compounds and methods for enhancing innate immune responses | |
| JP2015530404A5 (enExample) | ||
| MA40057A (fr) | Traitement thérapeutique de maladie cutanée au moyen de micro-organismes cutanés commensaux recombinants | |
| MX2021006253A (es) | Terapias génicas para enfermedad neurodegenerativa. | |
| JP2014513952A5 (enExample) | ||
| JP2018509388A5 (enExample) | ||
| BR112019009074A2 (pt) | composições, métodos e uso de transferência genética para o tratamento de doenças neurodegenerativas | |
| JP2015514115A5 (enExample) | ||
| EA201491513A1 (ru) | Рекомбинантные штаммы escherichia coli |